REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue5,872,2274,860,4274,103,728
Cost of Revenue397,061299,694392,709
Gross Profit5,475,1664,560,7333,711,019
Operating Expenses
Research Development2,075,1422,052,2951,620,577
Selling General and Administrative1,320,4331,177,697838,526
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss2,079,5911,330,7411,251,916
Income from Continuing Operations
Total Other Income/Expenses Net24,0396,269-12,578
Earnings Before Interest and Taxes2,103,6301,337,0101,239,338
Interest Expense25,1197,19514,241
Income Before Tax2,078,5111,329,8151,225,097
Income Tax Expense880,000434,293589,041
Minority Interest---
Net Income From Continuing Ops1,198,511895,522636,056
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income1,198,511895,522636,056
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares1,198,511895,522636,056